We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

Rapid Coronavirus Testing Kits for Research Use

Rapid Coronavirus Testing Kits for Research Use content piece image
Listen with
Speechify
0:00
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: 1 minute

With the imminent threat of the coronavirus (SARS-CoV-2) forcing countries worldwide into lockdown and putting a severe strain on healthcare services, MicrosensDx has responded by adapting its current range of infectious disease rapid detection kits to create a coronavirus detection product, suitable initially for research use.

The MicrosensDx RapiPrep® system is intended to enable highly sensitive SARS-CoV-2 detection in less than 25 minutes from taking a sample to test result. The portable, desktop kit will be used initially in scientific laboratories involved in vaccine and therapeutic research and development.

MicrosensDx is now engaged in a programme to gain CE accreditation for the SARS-CoV-2 test which will permit its sale and use in the diagnosis of the COVID-19 disease. The CE-marked kits aim to provide rapid “on demand” testing support alongside the large-scale hospital laboratory testing instruments and will also allow disease testing to take place in facilities such as clinics, doctor’s offices and in the workplace.

The key features of the RapiPrep® SARS-CoV-2 research use test are:

  • Any sample type is suitable: Including virus-containing culture media and tissue, clinical samples such as throat, nasal, sputum, faeces.
  • Rapid detection time: Less than 25 min to result.
  • Detection method: Detection of the viral RNA genome based on the MicrosensDx modified LAMP nucleic acid amplification technology, which is already in routine use in the company’s tuberculosis and norovirus clinical diagnostics products.
  • Accuracy: The RapiPrep® system incorporates the company’s proven magnetic bead-based virus extraction technology that gives enhanced sensitivity over other testing methods.
  • Reliability: The modified LAMP method incorporates procedure controls to prevent false negatives, which will be of critical importance in the future CE-marked test.
  • Safety: Immediate virus inactivation takes place inside the test cartridge.
  • Easy to operate: Three simple steps, suitable for semi-skilled operators.
  • Automated detection: The instrument has visual representation of test result and confirmation that the procedure control has run successfully.


The RapiPrep® system will be undergoing clinical assessment imminently within the UK to demonstrate its value as a rapid COVID-19 screening tool.